Epstein-Barr virus (EBV) is a member of the herpesvirus family that infects nearly 95% of adults worldwide. It’s best known as the cause of infectious mononucleosis (“mono”), but its significance goes well beyond that single illness. Once you’re infected, the virus stays in your body for life, quietly persisting in a type of white blood cell. For most people, this never causes problems. For a small number, it’s linked to certain cancers and autoimmune conditions.
How EBV Spreads
EBV spreads primarily through saliva, which is why mono earned the nickname “the kissing disease.” Sharing drinks, utensils, or toothbrushes can also transmit it. Less commonly, the virus can spread through breast milk, other body fluids, or organ transplantation. Because it’s so easily passed and most carriers show no symptoms, the vast majority of people pick it up during childhood or young adulthood without realizing it.
When children catch EBV in their early years, the infection usually produces no noticeable symptoms or looks like a mild cold. It’s when the first infection happens during adolescence or adulthood, often through intimate contact that involves a larger dose of the virus, that it’s more likely to trigger full-blown mono.
Mono: The Most Common EBV Illness
Symptoms of mono typically appear four to six weeks after you’re exposed to the virus. The hallmark signs include extreme fatigue, fever, a severe sore throat, headaches and body aches, swollen lymph nodes in the neck and armpits, and a swollen liver or spleen. Some people also develop a rash.
Most people recover in two to four weeks, though lingering fatigue can drag on for several more weeks. In some cases, symptoms persist for six months or longer. The swollen spleen is the symptom doctors watch most carefully because a spleen that’s enlarged from mono is vulnerable to rupture, which is why you’ll typically be told to avoid contact sports and heavy lifting during recovery.
How EBV Stays in Your Body
What makes EBV different from a virus like the flu is that your immune system never fully clears it. After the initial infection, the virus retreats into memory B cells, a type of immune cell that circulates in your blood. There, EBV enters a dormant state called latency. It carries its own genetic instructions that allow it to ride along silently as these cells divide, copying itself just enough to persist without triggering an immune response.
The virus has evolved several distinct “programs” of dormancy, each expressing different sets of viral genes. In its quietest state, it produces almost nothing detectable. In more active states, it can manipulate cell growth pathways and, in rare cases, push cells toward uncontrolled division. This is the mechanism behind EBV’s connection to certain cancers.
EBV and Cancer
EBV was the first virus ever linked to human cancer, and it’s now associated with several types. These include Burkitt lymphoma (a fast-growing cancer most common in parts of Africa), Hodgkin lymphoma, nasopharyngeal carcinoma (a cancer of the upper throat behind the nose, more prevalent in East and Southeast Asia), certain T-cell lymphomas, post-transplant lymphoproliferative disease in organ transplant recipients, and some cancers of the stomach and smooth muscle tissue.
It’s important to put this in perspective. Nearly everyone carries EBV, but these cancers are relatively rare. The virus is one piece of a larger puzzle that includes genetics, immune function, and environmental factors. Having EBV doesn’t mean you’ll develop cancer. It means the virus can, under specific circumstances, contribute to the process.
The Link to Multiple Sclerosis
One of the most significant recent findings about EBV is its connection to multiple sclerosis (MS). Research shows that MS in people who have never been infected with EBV is virtually nonexistent. A large English study tracking hospital records over 20 years found that people who had mono were nearly three times more likely to develop MS than the general population, with the risk peaking five to nine years after the mono diagnosis, when the rate was more than four times higher.
The relationship appears to go beyond simple correlation. Scientists now believe EBV infection may be a prerequisite for MS, and that the body’s intense immune response during mono may play an additional role in triggering the disease. This doesn’t mean mono causes MS in most people. It means that in genetically susceptible individuals, the immune disruption from EBV infection can set a process in motion years before any neurological symptoms appear.
Chronic Active EBV
In very rare cases, the virus doesn’t settle into quiet dormancy and instead causes ongoing, active disease. This condition, called chronic active Epstein-Barr virus disease (CAEBV), involves persistently high levels of the virus infecting T cells or natural killer cells rather than the B cells EBV normally targets. Diagnosis requires blood tests showing an EBV DNA level at or above 10,000 international units per milliliter along with confirmation that the virus has infected these unusual cell types.
CAEBV is a serious condition. There’s no standard drug treatment that cures it. Chemotherapy can be used to reduce the viral load and control symptoms, but the only treatment considered curative is a stem cell transplant. Patients who receive a transplant while their disease is in a controlled, inactive state have significantly better outcomes than those transplanted during active flares.
How EBV Is Diagnosed
Doctors use a panel of blood tests that look for different antibodies your immune system produces against EBV. The pattern of which antibodies are present tells your doctor whether you have a new infection, a past one, or have never been exposed.
- VCA IgM antibodies appear early in infection and disappear within four to six weeks. Their presence signals a current or very recent infection.
- VCA IgG antibodies peak two to four weeks after symptoms begin, then decline slightly but persist for life. They show up in both new and past infections.
- EBNA antibodies develop slowly, appearing two to four months after symptoms start, and persist for life. They’re absent during acute infection.
If your blood shows VCA IgM but no EBNA antibodies, that points to a primary (new) infection. If both VCA IgG and EBNA antibodies are present, it indicates a past infection from months or years earlier.
Treatment and Recovery
For the vast majority of people with EBV, including those with mono, there is no antiviral medication that effectively treats the infection. Management focuses on relieving symptoms: rest, fluids, over-the-counter pain relievers for fever and sore throat, and time. Most people recover fully without any lasting effects.
The lack of a targeted treatment is partly why EBV research has gained so much attention. With its connections to cancers and autoimmune diseases, the development of an EBV vaccine is an active area of scientific interest. For now, the practical takeaway is straightforward: EBV is extremely common, usually harmless, and for most people represents nothing more than a virus their immune system learned to keep in check long ago.